# Nutex Health Inc.: Form 10-Q for the period ended Mar 31, 2019

- Company: [Nutex Health Inc.](/companies/nutx.md) (CIK 1479681)
- Form: 10-Q
- Filed: 2019-05-20
- Accepted by EDGAR: May 20, 2019, 14:35 ET
- Period: 2019-03-31
- Accession: 0001607062-19-000235
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1479681/000160706219000235/igmb033119form10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1479681/000160706219000235/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-01-01 to 2019-03-31 | $5.3k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2019-01-01 to 2019-03-31 | $8.2k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2019-01-01 to 2019-03-31 | −$2.9k | us-gaap:GrossProfit |
| Operating income | 3 months, 2019-01-01 to 2019-03-31 | −$367.1k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-01-01 to 2019-03-31 | $133.3k | us-gaap:InterestExpense |
| Net income | 3 months, 2019-01-01 to 2019-03-31 | −$559.4k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-01-01 to 2019-03-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2019-01-01 to 2019-03-31 | −$101.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2019-03-31 | $7.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-03-31 | $44.4k | us-gaap:AssetsCurrent |
| Total assets | at 2019-03-31 | $2.4m | us-gaap:Assets |
| Total liabilities | at 2019-03-31 | $1.2m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-03-31 | $1.2m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2019-03-31 | 387,553,890 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 14,276 characters.

### FORWARD LOOKING STATEMENTS

This Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated by reference in this Form 10-Q which address activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future capital expenditures (including the amount and nature thereof), finding suitable merger or acquisition candidates, expansion and growth of the Company’s business and operations, and other such matters are forward-looking statements. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments as well as other factors it believes are appropriate in the circumstances.

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Factors that could adversely affect actual results and performance include, among others, potential fluctuations in quarterly operating results and expenses, government regulation, technology change and competition. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements.

### INTRODUCTION

### Introduction

iGambit is a company focused on the medical technology markets. Our primary focus is the expansion of our subsidiary HealthDatix™ Inc.

HealthDatix is a medical technology company that provides end to end Software-as-a-Service solutions, services and products via our HealthDatix Platform that manages, reports, and analyzes critical data, enabling healthcare and commercial organizations to deliver positive member outcomes.

### HealthDatix Platform Products and Services

#### Health Risk Assessment (HRA)

Our Health Risk Assessment (HRA) solution is a standardized method of collecting health risk data from patients or employees that can be used by Wellness Clinics, Insurance Companies, Third Party Administrators (TPA’s) and/or self insured companies to identify the health risks of their employee or patient population. Our HRA solution can be tailored to deliver the HRA and a Preventive Plan for all beneficiaries and their dependents.

Target Market : Insurance Companies, TPA’s and/or self-insured companies.

#### Annual Wellness Visit (AWV)

Our Annual Wellness Visit (AWV) solution allows for a mass check of patients with CMS to determine if and when they are eligible for an initial or subsequent AWV and identifies eligibility for other preventive screenings. Our proprietary algorithm determines a patients’ qualification for preventive screenings, health and lifestyle risks and if they have 2 or more qualifying chronic conditions that make them eligible for CCM. The program creates a 5-10 year preventive plan for the patient and meets all of CMS audit requirements to bill for the services. The AWV provides a proactive approach to patient care and increases practice revenue by identifying and executing CMS recommended screenings for the patient to catch early disease states before they become chronic conditions

Target Market: Medicare Programs including ACO’s, Primary Care Offices, Chronic Care Management and Non-Medicare including Wellness Clinics, Insurance Companies, Medicare Advantage Plans (MAP)

#### BioDatix HealthBand

Our BioDatix Health Band requires our Remote Patient Monitoring (RPM) solution that speaks to our FDA cleared Electronic House Call system. The BioDatix Health Band passively collects heart rate, blood pressure, blood oxygen every 15 minutes. It calculates sleep and steps and sends to our BioDatix iOS/Android app and then to our RPM solution.

Target Markets: Physician Groups, ACO’s, Healthcare Systems, Cardiovascular & Pulmonary Providers, Insurance Companies, Preventive Care for High Stress Jobs, Wellness Clinics.

#### BioDatix Remote Patient Monitoring

In addition to our BioDatix HealthBand, our RPM solution accepts data from multiple FDA approved devices on a patient’s health status, ie. blood pressure, weight, glucose levels, etc. It’s a product that is primarily for home bound patients that need remote monitoring vs. placement in a rehab center after hospital discharge. The information in our RPM solution can then be accessed by the physician/staff to determine the health status of the patient and whether or not a critical situation is at hand for the patient to go to the hospital, come in for a visit, or receive a nursing staff visit.

Target Markets: Physician Groups, ACO’s, Healthcare Systems, Cardiovascular & Pulmonary Providers, Insurance Companies, Preventive Care for High Stress Jobs, Wellness Clinics.

#### HealthDatix - Chronic Care Management (CCM) Program

Centers for Medicaid and Medicare Services (CMS) introduced the Chronic Care Management (CCM) program in 2015 with the goal of filling patient care gaps and providing patient care at home.

HealthDatix Chronic Care Management (CCM) service was established to provide better care by engaging patients between visits by providing remote monitoring of patients. eat better, exercise more, take their medications, and live healthier lives. The CCM program delivers 20 minutes of non-face-to-face care coordination to Medicare eligible beneficiaries with two or more chronic conditions.

Target Markets: Physician Groups, ACO’s, Healthcare Systems

***Assets.*** At March 31, 2019, we had $2,446,329 in total assets, compared to $2,618,466, at December 31, 2018. The decrease in total assets was primarily due to amortization of intangible assets from the acquisition of our HealthDatix subsidiary.

***Liabilities.*** At March 31, 2019, our total liabilities were $1,222,874 compared to $1,385,447 at December 31, 2018. Our current liabilities at March 31, 2019 consisted of accounts payable and accrued expenses of $570,331, accrued interest on notes payable of $20,939, amounts due to related parties of $139,753, deferred revenue of $5,467, notes payable of $52,500, convertible notes payable of $214,368 and derivative liability of $219,516, whereas our total liabilities at December 31, 2018 consisted of current liabilities including accounts payable and accrued expenses of $480,270, accrued interest on notes payable of $32,265, amounts due to related parties of $145,367, deferred revenue of $9,192, notes payable of $52,500, convertible notes payable of $377,611 and derivative liability of $288,242.

***Stockholders’ Equity.*** Our Stockholders’ Equity decreased to $1,223,455 at March 31, 2019 from $1,233,019 at December 31, 2018. This decrease was primarily due to an increase in accumulated deficit for the three months ended March 31, 2019.

### Three Months Ended March 31, 2019 as Compared to Three Months Ended March 31, 2018

***Revenues and Net Loss.*** We had $5,325 of revenue from our HealthDatix subsidiary and a net loss of $559,367 during the three months ended March 31, 2019, compared to revenue of $4,192 and a net loss of $610,033 for the three months ended March 31, 2018. The increase in revenue was due primarily to the revenue generated by our HealthDatix subsidiary.

***General and Administrative Expenses.*** General and Administrative Expenses decreased to $190,264 for the three months ended March 31, 2019 from $234,264 for the three months ended March 31, 2018. For the three months ended March 31, 2019 our General and Administrative Expenses consisted of corporate administrative expenses of $30,381, legal and accounting fees of $24,455 employee benefits expenses (health and life insurance) of $3,215, payroll expenses of $109,746, contract labor of $10,000, and transfer agent fees of 12,467. For the three months ended March 31, 2018 our General and Administrative Expenses consisted of corporate administrative expenses of $44,315, legal and accounting fees of $18,110, employee benefits expenses (health and life insurance) of $10,268, marketing expenses of $16,675, payroll expenses of $105,086, contract labor expense of $12,200, commissions and fees expenses of $21,000, and exchange filing fees of $6,610. The decreases from the three months ended March 31, 2018 to the three months ended March 31, 2019 relate primarily due to: (i) a decrease in employee benefits; (ii) a decrease in commissions and fees expenses; (iii) a decrease in contract labor expense; (iv) a decrease in marketing expense; and (v) a decrease in general and administrative costs associated with the operation of our HealthDatix subsidiary. Costs associated with our officers’ salaries and the operation of our HealthDatix subsidiary are expected to increase going forward, as we expand the business operations of HealthDatix which would likely increase our corporate administrative expenses.

***Other Income (Expense).*** We reported change in fair value of derivative liability of $53,163, loss on extinguishment of debt of $5,838, and interest expense of $133,253 for the three months ended March 31, 2019. We reported change in fair value of derivative liability of $118,101, loss on extinguishment of debt of $63,699, and interest expense of $16,264 for the three months ended March 31, 2018.

### Liquidity and Capital Resources

### General

As reflected in the accompanying consolidated financial statements, at March 31, 2019, we had $7,036 of cash and stockholders’ equity of $1,223,455. At December 31, 2018, we had $369 of cash and stockholders’ equity of $1,233,019.

Our primary capital requirements in 2019 are likely to arise from the expansion of our HealthDatix operations. It is not possible to quantify those costs at this point in time, in that they depend on HealthDatix’s business opportunities and the state of the overall economy. We anticipate raising capital in the private markets to cover any such costs, though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank.

While we believe in the viability of our strategy to improve HealthDatix’s sales volume, and in our ability to raise additional funds, there can be no assurances that we will be able to fully effectuate our business plan.

We believe we will continue to increase our cash position and liquidity for the foreseeable future. We believe we have enough capital to fund our present operations.

### Cash Flow Activity

Net cash used in operating activities was $101,719, for the three months ended March 31, 2019, compared to $273,204 for the three months ended March 31, 2018. Our primary use of cash flows from operating activities was from net losses of $559,367 and $610,033 for the three months ended March 31, 2019 and 2018, respectively. Additional contributing factors to the change were from depreciation expense of $247, amortization expense of $173,967, non-cash interest expense of $132,482, stock based compensation of $1,025, a loss on extinguishment of debt of $5,838, change in fair value of derivative liability of $53,163, a decrease in accounts receivable of $4,505, a decrease in inventory of $85, an increase in accounts payable and accrued expenses of $90,061, and a decrease in deferred revenue $3,725.

There were no cash flows from investing activities for the three months ended March 31, 2019 and 2018, respectively.

Net Cash provided by financing activities was $108,386 for the three months ended March 31, 2019 compared to $324,000 for the three months ended March 31, 2018. The cash flows provided by financing activities for the three months ended March 31, 2019 was primarily from $114,000 in proceeds from convertible debt, $6,386 in proceeds from related party loans, and $12,000 in repayments of related party loans. The cash flows provided by financing activities for the three months ended March 31, 2018 was primarily from $309,000 in proceeds from convertible debt and $15,000 in proceeds from the sale of common stock.

### Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

## Controls and procedures

As filed, 1,907 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of March 31, 2019, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting

### Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Filed May 20, 2019.
Source: SEC EDGAR, the filing index for accession 0001607062-19-000235. Last ingested by Listed: Nov 14, 2026, 12:46 ET. No prices; not investment advice.
